Allergy Therapeutics plc - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Allergy Therapeutics plc - Product Pipeline Review - 2014" provides data on the Allergy Therapeutics plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Allergy Therapeutics plc's corporate website, SEC filings, investor presentations and featured press releases, both from Allergy Therapeutics plc and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Allergy Therapeutics plc - Brief Allergy Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergy Therapeutics plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergy Therapeutics plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergy Therapeutics plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Allergy Therapeutics plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Allergy Therapeutics plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergy Therapeutics plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergy Therapeutics plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergy Therapeutics plc and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Allergy Therapeutics plc Snapshot 5
Allergy Therapeutics plc Overview 5
Key Information 5
Key Facts 5
Allergy Therapeutics plc - Research and Development Overview 6
Key Therapeutic Areas 6
Allergy Therapeutics plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Allergy Therapeutics plc - Pipeline Products Glance 10
Allergy Therapeutics plc - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
Allergy Therapeutics plc - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Allergy Therapeutics plc - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Allergy Therapeutics plc - Drug Profiles 15
Pollinex Quattro Grass 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Pollinex Ragweed 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Pollinex Quattro Tree 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MPL-Based Allergy Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Pollinex Quattro Japanese Cedar 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Allergy Therapeutics plc - Pipeline Analysis 23
Allergy Therapeutics plc - Pipeline Products by Therapeutic Class 23
Allergy Therapeutics plc - Pipeline Products by Route of Administration 24
Allergy Therapeutics plc - Pipeline Products by Molecule Type 25
Allergy Therapeutics plc - Recent Pipeline Updates 26
Allergy Therapeutics plc - Dormant Projects 27
Allergy Therapeutics plc - Company Statement 28
Allergy Therapeutics plc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables
Allergy Therapeutics plc, Key Information 5
Allergy Therapeutics plc, Key Facts 5
Allergy Therapeutics plc - Pipeline by Indication, 2014 7
Allergy Therapeutics plc - Pipeline by Stage of Development, 2014 8
Allergy Therapeutics plc - Monotherapy Products in Pipeline, 2014 9
Allergy Therapeutics plc - Pre-Registration, 2014 10
Allergy Therapeutics plc - Phase III, 2014 11
Allergy Therapeutics plc - Phase II, 2014 12
Allergy Therapeutics plc - Phase I, 2014 13
Allergy Therapeutics plc - Preclinical, 2014 14
Allergy Therapeutics plc - Pipeline by Therapeutic Class, 2014 23
Allergy Therapeutics plc - Pipeline by Route of Administration, 2014 24
Allergy Therapeutics plc - Pipeline by Molecule Type, 2014 25
Allergy Therapeutics plc - Recent Pipeline Updates, 2014 26
Allergy Therapeutics plc - Dormant Developmental Projects,2014 27
Allergy Therapeutics plc, Subsidiaries 29